Menu
Back to Journals » Journal of Asthma and Allergy » Volume 11
Anaphylaxis: getting to the point (and price) of diagnosis and treatment
Authors Moss RB
Received 10 April 2018
Accepted for publication 16 April 2018
Published 20 June 2018 Volume 2018:11 Pages 109—110
DOI https://doi.org/10.2147/JAA.S170650
Checked for plagiarism Yes
Editor who approved publication: Dr Luis Garcia-Marcos
Ronald B Moss
Adamis Pharmaceuticals Corporation, San Diego, CA, USA
Anaphylaxis was first described by Charles Richet and Paul Portier in 1901 as an immune reaction that is the opposite of immune protection resulting from vaccination.1 Anaphylaxis can be better categorized into both immunoglobulin E (IgE) and non-IgE pathways.2 Between 1.6% and 5.1% of the Americans are estimated to experience anaphylaxis, which can be fatal.3 The common triggers for an acute anaphylactic episode are foods, drugs, and venoms. Ultimately, a number of mediators are released that explain the clinical symptoms of flushing, pruritus, urticaria, shortness of breath, bronchospasm, hypotension, and cardiovascular collapse.2 Epinephrine injection is the evidence-based treatment for acute anaphylaxis, and delayed epinephrine administration is a risk factor for fatal anaphylaxis.3 However, like many other effective therapies in medicine, there remain barriers to treatment of anaphylaxis.
Disclosure
The author reports no conflicts of interest in this work.
References
Ring J. editor. Anaphylaxis. Chem Immunol Allergy. Basel: Karger; 2010:1–11. | ||
Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 140(2):321–333. | ||
Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169–1178. | ||
Yue D, Ciccolini A, Avilla E, Waserman S. Food allergy and anaphylaxis. J Asthma Allergy. 2018;11:111–120. | ||
Jiminez-Rodriguez TW, Garcia-Neuer M, Alenazy L, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes and biomarkers. J Asthma Allergy. 2018;11:121–142. | ||
Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. J Asthma Allergy. 2018;11:143–151. | ||
Westermann-Clark E, Pepper AN, Lockey RF. Economic considerations in the treatment of systemic allergic reactions. J Asthma Allergy. 2018;11:153–158. | ||
Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol. 2010;10:354–361. | ||
Moss RB, Daniels K, Moll T, Carlo DJ. Human factors study in untrained adolescents comparing an epinephrine prefilled syringe (Symjepi™) with EpiPen® autoinjector. Annals of Allergy, Asthma & Immunology. 2018;120(5):540–541. | ||
Moss RB, Daniels K, Moll T, Carlo DJ. Human Factors Study of a Newly Approved Epinephrine Prefilled syringe (PFS) for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis. AAAAI Meeting, March 3; 2018; Orlando, FL, abstract 124. | ||
Simons FER, Edwards ES, Read EJ, Clark S, Liebel EL. Voluntary reported unintentional injections from epinephrine auto-injectors. JACI. 2010;125:419–423. | ||
Copeland CJ. Accidental digital epinephrine injection: to treat or not to treat? Can Fam Physician. 2014(60):726–728. | ||
Brown JR. Turi, Lacerations and embedded needles due to Epipen use in children. J Allergy Clin Immunol Pract. 2016;4(3):549–551. | ||
Redmond M, Stukus D. Lacerations associated with use of epinephrine autoinjectors in children. J Allergy Clin Immunol Pract. 2016;4(3):2213–2218. | ||
Reuters. U.S. Mylan says EpiPen manufacturing partner to expand device recall [press release]. Health News. 2017 [April 1]. Available from: http://www.reuters.com/article/us-mylan-nl-recall-epipen/mylan-says-epipen-manufacturing-partner-to-expand-device-recall-idUSKBN1722XB. Accessed May 16, 2018. | ||
Reuters. U.S. FDA warns of problems with EpiPen manufacturing plant [press release]. U.S. Legal News. 2017 [September 8]. Available from: https://www.reuters.com/article/us-pfizer-mylan-epipen/u-s-fda-warns-of-problems-witepipen-manufacturing-plant-idUSKCN1BI2Y5. Accessed May 16, 2018. | ||
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Asthma and Allergy ‘Editorial’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Asthma and Allergy editors. While all reasonable steps have been taken to confirm the content of each Editorial, Dove Medical Press accepts no liability in respect of the content of any Editorial, nor is it responsible for the content and accuracy of any Editorial. |
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.